

**REMARKS**

Applicants have amended claim 1 of U.S. Patent No. 5,760,069, and have added new claims 8-9. In accordance with 37 C.F.R. § 1.173(c), Applicants have provided herein a table of exemplary support for the claim amendments and the new claims. Claims 1-9 are pending in the application.

**TABLE OF EXEMPLARY SUPPORT**

<b>Claim</b>	<b>Exemplary Support for Claim Amendments/New Claims</b>
1	The study disclosed in the specification had a maintenance period of ranging from six months to 12 months, but the total length of the maintenance period was open ended because patients had the option of continuing to receive carvedilol after the end of the study. See, e.g., col. 7, ln. 2-5 ("The maintenance phase of each study ranged from six to 12 months, after which patients had the option of receiving open-label carvedilol in an extension study."). Further, throughout the specification, the treatment is directed to decreasing the risk of mortality caused by congestive heart failure. See, e.g., col. 1, ln. 6-12 ("The present invention relates to a new method of treatment ... for decreasing the mortality of patients suffering from congestive heart failure (CHF)."); col. 3, ln. 44-46 ("carvedilol [is] able to decrease the mortality resulting from CHF in humans by about 67 percent."); col. 6, ln. 5-6 ("This represented a reduction in risk of death by [carvedilol] of 67% ....").
8	See exemplary support for claim 1, above.
9	See, e.g., col. 5, ln. 60-65 ("After a common screening period, patients with class II-IV CHF ... and an ejection fraction of <0.35 were assigned to one of four protocols ...."), col. 6, ln. 7-8 ("The treatment was similar in patient with class II and class III-IV symptoms.").

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER <sup>LLP</sup>


1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: November 25, 2003

By:   
Mark J. Feldstein  
Reg. No. 46,693

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)